

Supplementary Online Content


de Almeida Carvalho LM, de Oliveira Saporì Averlar S, Haslam A, Gill J, Prasad V. Estimation of percentage of patients with fibroblast growth factor receptor alterations eligible for off-label use of erdafitinib. *JAMA Netw Open*. 2019;2(11):e1916091. doi:10.1001/jamanetworkopen.2019.16091

eFigure. Estimated Number of Individuals With Any *FGFR* Alteration and Percentage of Eligibility That Is Attributed to Approved or Off-label Use of *FGFR* Inhibitors

eTable. Ongoing Studies of Erdafitinib Registered Through ClinicalTrials.gov

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Estimated Number of Individuals With Any *FGFR* Alteration and Percentage of Eligibility That Is Attributed to Approved or Off-label Use of *FGFR* Inhibitors



eTable. Ongoing Studies of Erdafitinib Registered Through ClinicalTrials.gov

Cancer Type	Title of Case Study/trial	Type of study	Primary outcome	Start date-estimated completion date	# of Patients in trial	Clinical trials NCT#
Advanced solid cancers	A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers	Phase I, non randomized	Safety	August 31, 2018 – July 8, 2021	30	NCT03547037
Urothelial	A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations	Phase I/II, randomized	Safety and ORR	April 5, 2018 – June 17, 2021	102	NCT03473743
Advanced malignant solid neoplasm	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)	Phase II, non-randomized	ORR	Nov 6, 2017 – December 31, 2024	49	NCT03210714
Neoplasm	A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma	Phase II, non-randomized	ORR	July 8, 2016 – August 31, 2020	55	NCT02699606
Breast	Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer	Phase I, non-randomized	Safety	August 10, 2017 – September 2022	32	NCT03238196
Urothelial	A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants	Phase III,	OS	March 23, 2018 –	631	NCT03390504

	With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations	randomized		November 5, 2021		
Lung	FGFR Inhibitor in FGFR Dysregulated Cancer	Phase II, non-randomized	ORR	March 15, 2019 – March 15, 2022	50	NCT03827850
Multiple myeloma	Myeloma-Developing Regimens Using Genomics (MyDRUG)	Phase I/II, non-randomized	ORR	April 1, 2019 – February 10, 2024	228	NCT03732703
Advanced malignant neoplasm	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Phase II, non-randomized	ORR	August 12, 2015 – June 30, 2022	6452	NCT02465060
Advanced malignant neoplasm	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Phase II, non-randomized	ORR	July 24, 2017 – September 30, 2027	1000	NCT03155620